Cedars-Sinai researchers have found a clinical trial which could help – if the multimodal care before treatment has been extracted.
The Alliance-Deficit Treatment-Acute (ADTA) study studied patients who recently started a multidisciplinary treatment for opioid use disorder a form of addiction that leads to a prolonged and severe withdrawal of everyday activities that lead to lasting physical and mental health problems.
MJ Ahn and a team of science.
Sol Aron Abramson MD professor and the John W. and Elsie L. Madigan Professor in Neuroscience at Cedars-Sinai published the study in November 2019. The patient group included many people addicted to opioids as well as people with other forms of addiction.
Participants were randomly assigned into one of three treatment groups: a standard medium and high dose of buprenorphine sulfate (which has been approved by the Food and Drug Administration as a non-pharmacological adjunct to some of the most popular narcotic pain medications); an escitalopram sodium (a stronger form of heroin); or biologics -regardless of the type of opioid they were taking.
Cedars-Sinai is among the first in the country to pursue the multidisciplinary treatment by combining multidisciplinary care – which includes treating addiction helping family members maintain healthy habits and providing participants with programs for proper nutrition and exercise.
Heading into the trial patients pain patterns were tracked over a period of 15 weeks. Prior to the treatment they completed the Structured Clinical Brain Assessment of Deregitation (SDAD-D) questionnaire which assessed their moderation-like response (i.e. no longer seeking or attempting to acquire status) and their arousal (the extent to which they hunt for pleasure working memory or intellectual activity) and their anxiety (the degree of anxietyinduced by pain).